Karo Pharma AB (Karo Pharma AB) EBIT per Share : $0.10 (TTM As of Jun. 2022)

View and export this data going back to . Start your Free Trial

What is Karo Pharma AB EBIT per Share?

Karo Pharma AB's EBIT per Share for the three months ended in Jun. 2022 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $0.10.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Karo Pharma AB's EBIT per Share or its related term are showing as below:

KARBF's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.25
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Karo Pharma AB's EBIT for the three months ended in Jun. 2022 was $0.0 Mil.

Karo Pharma AB EBIT per Share Historical Data

The historical data trend for Karo Pharma AB's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB EBIT per Share Chart

Karo Pharma AB Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT per Share

Get a 7-Day Free Trial

0.08

0.33

0.10

0.13

0.10

Karo Pharma AB Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Jun22
EBIT per Share	Get a 7-Day Free Trial															0.07	0.02	0.05	-0.03	-

Karo Pharma AB EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Karo Pharma AB's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

	EBIT per Share		(A: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	21.499	/	226.441
=	0.09

Karo Pharma AB's EBIT per Share for the quarter that ended in Jun. 2022 is calculated as

	EBIT per Share		(Q: Jun. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0	/	249.144
=	0.00

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.10

Karo Pharma AB (OTCPK:KARBF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Karo Pharma AB EBIT per Share Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Karo Pharma AB (Karo Pharma AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22

Website

https://www.karopharma.com

Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (Karo Pharma AB) Headlines

From GuruFocus

Avista Capital Partners To Sell Trimb To Karo Pharma

By PRNewswire PRNewswire • 06-25-2019